source
- Amid bepirovirsen triumph, GSK quietly scraps trial of next-gen hep B therapyGSK may have cemented its hepatitis B credentials with Tuesday’s landmark FDA nod for its “functional cure” bepirovirsen, but the pharma continues to rethink its strategy for next-gen candidates.Fierce Biotech · 5h ago↗ source
- Astellas links up with AI Proteins in $400M computational d rugdiscovery dealJapan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially worth $400 million.Fierce Biotech · 6h ago↗ source
- Genmab faces steep revenue cliff as Darzalex patents expire, eyes pivotal Epkinly readoutGenmab relies heavily on Darzalex, a cancer drug co‑developed with Johnson & Johnson, which currently provides about 90% of the company’s sales. U.S. patents for Darzalex are set to expire in 2029,…